Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 251-254
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.251
Cardiotoxicity induced by fluoropyrimidine drugs in the treatment of gastrointestinal tumors
Mo-Wei Kong, Feng-Di Sun, Zhen-Ying Pei, Li Xu, Ze-Bi Wang, Yan Chen, Shu-Qing Tang, Ting-Fang Yang, Guo-Xiang He
Mo-Wei Kong, Feng-Di Sun, Zhen-Ying Pei, Li Xu, Ze-Bi Wang, Yan Chen, Shu-Qing Tang, Guo-Xiang He, Department of Cardiology, Guiqian International General Hospital, Guiyang 550018, Guizhou Province, China
Ting-Fang Yang, Department of Oncology, Guiqian International General Hospital, Guiyang 550018, Guizhou Province, China
Author contributions: He GX and Yang TF provided crucial suggestions and guidance for the writing; Kong MW wrote the manuscript; Chen Y, Sun FD, Pei ZY, Wang ZB and Tang SQ reviewed and revised the manuscript; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ting-Fang Yang, MD, Doctor, Department of Oncology, Guiqian International General Hospital, No. 1 Dongfeng Avenue, Wudang, Guiyang 550018, Guizhou Province, China. 672539517@qq.com
Received: September 23, 2023
Peer-review started: September 23, 2023
First decision: December 26, 2023
Revised: December 28, 2023
Accepted: January 19, 2024
Article in press: January 19, 2024
Published online: February 15, 2024
Processing time: 131 Days and 20 Hours
Core Tip

Core Tip: This editorial focuses on the occurrence, clinical characteristics, and risk factors of fluoropyrimidine drug-related cardiotoxicity in patients with gastrointestinal tumors. Despite advancements in diagnostic and therapeutic techniques for digestive system tumors, treatment-related cardiotoxicity rates have been increasing, impacting the survival and prognosis of cancer patients. Fluoropyrimidine drugs, widely used in treating malignant tumors, including gastrointestinal tumors, are the second largest class of drugs associated with cardiotoxicity. However, there is often a lack of awareness or understanding regarding their cardiotoxic effects and associated risks.